<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755325</url>
  </required_header>
  <id_info>
    <org_study_id>RJ-CYP001</org_study_id>
    <nct_id>NCT01755325</nct_id>
  </id_info>
  <brief_title>Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+</brief_title>
  <official_title>Phase III Study of Compound Realgar Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult Patients With Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Junmin Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is an open-label, randomized, double blind, placebo-controlled parallel-group,
      multi-center study to evaluate the efficacy and safety of Compound realgar formula
      Realgar-Indigo naturalis Tablet combined with Imatinib will be compared with imatinib alone
      in adult patients with diagnosed Philadelphia chromosome-positive (Ph+) chronic myelogenous
      leukemia in the chronic phase (CML-CP).
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    not enough patients
  </why_stopped>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the rate of Major molecular response（MMR） at 12 months</measure>
    <time_frame>12 months of follow-up from the start of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">680</enrollment>
  <condition>Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Compound realgar natural indigo Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.
imatinib,0.4g,qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablet,65mg/kg/d, from day1 to day14,every 4 weeks.
imatinib 0.4g qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound realgar natural indigo Tablet</intervention_name>
    <description>Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.
imatinib,0.4g,qd</description>
    <arm_group_label>Compound realgar natural indigo Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients, age &gt;= 18 years and &lt;= 75 years.

          2. Eastern Cooperative Oncology Group （ECOG） performance status (PS) score 0, 1, or 2.

          3. Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of
             Philadelphia chromosome positive.(Ph+ CML-CP)

          4. Ph+ Chronic myelogenous leukemia in chronic phase patients within the first 12 months
             of diagnosis.

          5. Adequate end organ function as defined by:

        (1). Alanine transaminase（ALT）, Aspartate transaminase（AST） &lt;=2.5 x upper limit of
        normal（ULN）.

        (2). Total bilirubin &lt;= 1.5 x ULN. (3).Cr &lt;= 1.5 x ULN. (4). Serum amylase and lipase &lt;=
        1.5 x ULN. 6. Signed informed consent.

        Exclusion Criteria:

        1. Previously received or be receiving any of the following medical treatment for CML:

          1. . Treatment with Busulfan within 1 day prior to study entry.

          2. . Treatment with interferon-alpha within 2 days prior to study entry.

          3. . Treatment with hydroxyurea within 1 day prior to study entry.

          4. . Treatment with homoharringtonine within 14 days prior to study entry.

          5. . Treatment with Cytosine arabinoside within 28 days prior to study entry.

          6. . Surgery (Including hematopoietic stem cell transplantation therapy)

          7. . Treatment with anthracyclines, or etoposide within 21 days prior to study entry.

        2. Treatment with any tyrosine kinase inhibitor(s) or arsenic reagent prior to study entry
        3. Patients who are: (a) pregnant, (b) breast feeding, (c) female or male of childbearing
        potential unwilling to use contraceptive precautions throughout the trial.

        4. Major surgery within 4 weeks prior to randomization or who have not recovered from prior
        surgery.

        5. Patients who have not recovered from toxic reaction of prior similar treatment evaluated
        by investigators.

        6. Impaired cardiac function including any one of the following:

          1. LVEF &lt; 45%.

          2. . Complete left bundle branch block.

          3. . Use of a ventricular-paced pacemaker.

          4. . Congenital long QT syndrome.

          5. . History or presence of ventricular, clinically significant atrial tachyarrhythmias

          6. . History or presence of clinically significant bradyarrhythmia.(heart rate
             persistently less than 50/min)

          7. . QTcF &gt; 450 msec for male or 470 msec for female.

          8. . History of clinically documented myocardial infarction or unstable angina (during
             the last 12 month).

          9. .Any other severe heart disease. 7. Patients with active, uncontrolled psychiatric
             disorders, without insight and the ability of exact expression.

        8. Uncontrolled medical conditions:

          1. .Uncontrolled diabetes with fasting blood-glucose &gt;200mg/dl (11.1mmol/L),or with
             combined symptoms (nephropathy, peripheral neuropathy).

          2. . Uncontrolled hypertension.

          3. . Active or uncontrolled infection (persistent fever and worsening of the clinical
             symptoms) 9. Impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of the tested drug (e.g., ulcerative disease,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel
             resection, or gastric bypass surgery).

        10. History of chronic pancreatitis or history of acute pancreatitis within 1 year of study
        entry.

        11. Acute or chronic uncontrolled liver disease or severe renal disease considered
        unrelated to CML.

        12. Patients actively receiving therapy with strong CYP3A4 inhibitors, strong CYP3A4
        inducers or any medications being potential to prolong the QT interval and the treatment
        cannot be either discontinued or switched to a different medication prior to starting study
        drug.

        13. Treatment with other investigational agents (defined as not used in accordance with the
        approved indication) within 4 weeks prior to randomization.

        14. Known to be allergic to the study drugs, including crude drug or adjuvant. 15. As
        investigators evaluate, the patients do not fit to join the study (such as with severe
        complications) .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saijuan Chen, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Runjin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Union Hospital medical college Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The NO.1 People's Hospital of Huaian</name>
      <address>
        <city>Huaian</city>
        <state>Jiangsu</state>
        <zip>223002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital Affiliated to Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The FIrst Affiliated Hospital, College of Medicine, Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital, College of Medicine, Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Tumor Hospital of Jiangxi</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The NO.1 Hospital of Nanchang</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>333008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital-Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The FIrst Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Peking University</name>
      <address>
        <city>Peking</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Junmin Li</investigator_full_name>
    <investigator_title>Director of hematology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

